121 related articles for article (PubMed ID: 35046341)
1. [A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Kagawa Y; Inoue A; Nishizawa Y; Kawai K; Ohta T; Hata T; Naito A; Komatsu H; Miyazaki Y; Tomokuni A; Motoori M; Fujitani K; Kato T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):1819-1821. PubMed ID: 35046341
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial.
Gruenberger T; Bridgewater J; Chau I; García Alfonso P; Rivoire M; Mudan S; Lasserre S; Hermann F; Waterkamp D; Adam R
Ann Oncol; 2015 Apr; 26(4):702-708. PubMed ID: 25538173
[TBL] [Abstract][Full Text] [Related]
3. [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Nishii T; Uchima Y; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Aomatsu N; Iwauchi T; Morimoto J; Nakazawa K; Tei S; Takeuchi K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):1705-1707. PubMed ID: 28133105
[TBL] [Abstract][Full Text] [Related]
4. FOLFOXIRI Plus Bevacizumab as Conversion Therapy for Patients With Initially Unresectable Metastatic Colorectal Cancer: A Systematic Review and Pooled Analysis.
Tomasello G; Petrelli F; Ghidini M; Russo A; Passalacqua R; Barni S
JAMA Oncol; 2017 Jul; 3(7):e170278. PubMed ID: 28542671
[TBL] [Abstract][Full Text] [Related]
5. [Laparoscopic Abdominoperineal Resection Following Intensive Chemotherapy for Stage Ⅳ Rectal Cancer with Unresectable Metastases].
Nakatsukasa R; Hata T; Hayashi N; Urabe S; Hayashi K; Nakagawa T; Michiura T; Yamabe K
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2260-2262. PubMed ID: 33468927
[TBL] [Abstract][Full Text] [Related]
6. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
[TBL] [Abstract][Full Text] [Related]
7. [A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab].
Shigoka M; Enomoto M; Wada T; Mazaki J; Kuwabara H; Ishizaki T; Ishibashi Y; Nagakawa Y; Katsumata K; Tsuchida A
Gan To Kagaku Ryoho; 2019 Apr; 46(4):796-798. PubMed ID: 31164539
[TBL] [Abstract][Full Text] [Related]
8. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
9. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Rossini D; Lonardi S; Antoniotti C; Santini D; Tomasello G; Ermacora P; Germani MM; Bergamo F; Ricci V; Caponnetto S; Moretto R; Zaniboni A; Pietrantonio F; Buonadonna A; Ritorto G; Masi G; Latiano TP; Rapisardi S; Falcone A; Cremolini C
Br J Cancer; 2021 Jan; 124(1):183-190. PubMed ID: 33024268
[TBL] [Abstract][Full Text] [Related]
10. [Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Nemoto T; Endo S; Isohata N; Takayanagi D; Nemoto D; Aizawa M; Utano K; Togashi K; Oshibe I; Soeta N; Saito T
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2410-2412. PubMed ID: 32156948
[TBL] [Abstract][Full Text] [Related]
11. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Loupakis F; Cremolini C; Masi G; Lonardi S; Zagonel V; Salvatore L; Cortesi E; Tomasello G; Ronzoni M; Spadi R; Zaniboni A; Tonini G; Buonadonna A; Amoroso D; Chiara S; Carlomagno C; Boni C; Allegrini G; Boni L; Falcone A
N Engl J Med; 2014 Oct; 371(17):1609-18. PubMed ID: 25337750
[TBL] [Abstract][Full Text] [Related]
12. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
[TBL] [Abstract][Full Text] [Related]
13. [A Case of Recurrent Rectal Cancer with Acute Lower Extremity Arterial Occlusion during Treatment with Bevacizumab].
Okano M; Hara T; Hata T; Tanizaki K; Takayama O; Kim Y; Imamoto H; Hasegawa J
Gan To Kagaku Ryoho; 2023 Mar; 50(3):404-406. PubMed ID: 36927924
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
15. Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
Bhatti T; Moser M; Tan KT; Chalchal H; Souied O; Le D; Shaw J; Zaidi A; Gill D; Ahmed S
J Gastrointest Cancer; 2022 Jun; 53(2):427-433. PubMed ID: 33779898
[TBL] [Abstract][Full Text] [Related]
16. Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab.
Loupakis F; Schirripa M; Caparello C; Funel N; Pollina L; Vasile E; Cremolini C; Salvatore L; Morvillo M; Antoniotti C; Marmorino F; Masi G; Falcone A
Br J Cancer; 2013 Jun; 108(12):2549-56. PubMed ID: 23703247
[TBL] [Abstract][Full Text] [Related]
17. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
18. Modified FOLFOXIRI With or Without Cetuximab as Conversion Therapy in Patients with RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer: The FOCULM Multicenter Phase II Trial.
Hu H; Wang K; Huang M; Kang L; Wang W; Wang H; Qiu M; Lin R; Zhang H; Lan P; Wu X; Liu G; Wan Y; Liu M; Zhou Z; Huang Y; Li F; Zhang J; Cai Y; Ma T; Zhou J; Wang H; Ling J; Cai Y; Wu Z; Luo S; Ling L; Deng Y
Oncologist; 2021 Jan; 26(1):e90-e98. PubMed ID: 33400355
[TBL] [Abstract][Full Text] [Related]
19. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.
Cremolini C; Casagrande M; Loupakis F; Aprile G; Bergamo F; Masi G; Moretto R R; Pietrantonio F; Marmorino F; Zucchelli G; Tomasello G; Tonini G; Allegrini G; Granetto C; Ferrari L; Urbani L; Cillo U; Pilati P; Sensi E; Pellegrinelli A; Milione M; Fontanini G; Falcone A
Eur J Cancer; 2017 Mar; 73():74-84. PubMed ID: 27986363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
